drugset
drugset / Trial / NCT05980507

An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma

NCT05980507 ↗

Phase 1 Withdrawn The First Affiliated Hospital of Soochow University
NaSingle-groupOpen-labelTreatment

Summary

An open label, single-arm clinical study evaluating the safety and efficacy of ICI201 infusion in relapsed/refractory multiple myeloma

Timeline

Start
2023-10-09
Primary completion
2023-10-18
Completion
2023-10-18

Outcome

Outcome not reported

Stopped (Business): “Molecular development strategy adjustment”

Drugs

EvaluationDrugModalityDoseRoute
Subject ICI201 Cell therapy — —

Indications

refractory plasma cell neoplasm